AU2021369835A1 - Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof - Google Patents

Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof Download PDF

Info

Publication number
AU2021369835A1
AU2021369835A1 AU2021369835A AU2021369835A AU2021369835A1 AU 2021369835 A1 AU2021369835 A1 AU 2021369835A1 AU 2021369835 A AU2021369835 A AU 2021369835A AU 2021369835 A AU2021369835 A AU 2021369835A AU 2021369835 A1 AU2021369835 A1 AU 2021369835A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
binding domain
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021369835A
Other languages
English (en)
Other versions
AU2021369835A9 (en
Inventor
David Campbell
Thomas R. DIRAIMONDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janux Therapeutics Inc
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of AU2021369835A1 publication Critical patent/AU2021369835A1/en
Publication of AU2021369835A9 publication Critical patent/AU2021369835A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021369835A 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof Pending AU2021369835A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063107942P 2020-10-30 2020-10-30
US63/107,942 2020-10-30
US202063123329P 2020-12-09 2020-12-09
US202063123327P 2020-12-09 2020-12-09
US63/123,327 2020-12-09
US63/123,329 2020-12-09
US202163141268P 2021-01-25 2021-01-25
US63/141,268 2021-01-25
US202163187719P 2021-05-12 2021-05-12
US202163187699P 2021-05-12 2021-05-12
US202163187690P 2021-05-12 2021-05-12
US63/187,690 2021-05-12
US63/187,719 2021-05-12
US63/187,699 2021-05-12
US202163189843P 2021-05-18 2021-05-18
US63/189,843 2021-05-18
PCT/US2021/057384 WO2022094299A2 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2021369835A1 true AU2021369835A1 (en) 2023-06-01
AU2021369835A9 AU2021369835A9 (en) 2024-07-11

Family

ID=81384468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021369835A Pending AU2021369835A1 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Country Status (8)

Country Link
US (1) US20230406937A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237013A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548443A (cg-RX-API-DMAC7.html)
KR (1) KR20230136913A (cg-RX-API-DMAC7.html)
AU (1) AU2021369835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196726A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005081A (cg-RX-API-DMAC7.html)
WO (1) WO2022094299A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
CN116981682A (zh) * 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
KR20250024874A (ko) * 2022-04-04 2025-02-19 재눅스 테라퓨틱스 인크. Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법
AR129202A1 (es) * 2022-05-04 2024-07-31 Janux Therapeutics Inc Anticuerpos activados por tumores que se dirigen a trop2 y usos de estos
EP4519326A4 (en) * 2022-05-04 2026-05-06 Janux Therapeutics Inc TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
EP4615514A2 (en) * 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2024100451A2 (en) * 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
WO2024237744A1 (ko) * 2023-05-18 2024-11-21 서울대학교산학협력단 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도
WO2025026356A1 (zh) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用
WO2025090973A2 (en) * 2023-10-27 2025-05-01 Xencor, Inc. Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
WO2025097024A1 (en) * 2023-11-03 2025-05-08 Janux Therapeutics, Inc. Antibodies for targeting cd28 and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
US20180179282A1 (en) * 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017337073A1 (en) * 2016-09-30 2019-04-18 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
WO2019005637A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
CN112513077B (zh) * 2018-07-09 2025-05-16 上海岸迈生物科技有限公司 高效表达的egfr和pd-l1双特异性结合蛋白
US20200223925A1 (en) * 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
CR20210326A (es) * 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
EP3941941A1 (en) * 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies

Also Published As

Publication number Publication date
WO2022094299A2 (en) 2022-05-05
CA3196726A1 (en) 2022-05-05
EP4237013A2 (en) 2023-09-06
JP2023548443A (ja) 2023-11-16
KR20230136913A (ko) 2023-09-27
US20230406937A1 (en) 2023-12-21
WO2022094299A3 (en) 2022-09-29
EP4237013A4 (en) 2025-02-26
MX2023005081A (es) 2023-06-15
AU2021369835A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
AU2021369835A9 (en) Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
WO2022125576A1 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US20230357447A1 (en) Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
EP4259202A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
US20240254241A1 (en) Antibodies targeting egfr and cd3 and uses thereof
EP4200337A1 (en) Antibodies targeting trop2 and cd3 and uses thereof
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
US20250154278A1 (en) Optimized antibodies targeting trop2 and uses thereof
CN120435318A (zh) 靶向egfr和cd3的抗体及其用途
CN117098562A (zh) 用于靶向cd28和pd-l1的多特异性抗体及其使用方法
US20260049137A1 (en) Optimized antibodies targeting cd3 and uses thereof
CN116997573A (zh) 靶向psma和cd3的抗体及其用途
WO2026096557A2 (en) Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN121443645A (zh) 靶向cd3的肿瘤活化的抗体及其用途